Efecto de paricalcitol sobre el metabolismo mineralóseo en pacientes trasplantados renales con hiperparatiroidismo secundario

Coyne, 2013, Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: Results of the VITAL study, Nephrol Dial Transplant, 28, 2260, 10.1093/ndt/gft227 Coyne, 2006, Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD, Am J Kidney Dis, 47, 263, 10.1053/j.ajkd.2005.10.007 Tonbul, 2012, Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study, Ren Fail, 34, 297, 10.3109/0886022X.2011.647298 Sprague, 2003, Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism, Kidney Int, 63, 1483, 10.1046/j.1523-1755.2003.00878.x Ross, 2008, Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis, Am J Nephrol, 28, 97, 10.1159/000109398 Ketteler, 2012, Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: Results of the IMPACT SHPT study, Nephrol Dial Transplant, 27, 3270, 10.1093/ndt/gfs018 Vulpio, 2011, Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size, Hemodial Int, 15, 69, 10.1111/j.1542-4758.2010.00514.x Lund, 2010, Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients, Am J Nephrol, 31, 165, 10.1159/000266204 Brown, 2002, Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport, J Lab Clin Med, 139, 279, 10.1067/mlc.2002.122819 Evenepoel, 2004, Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study, Nephrol Dial Transplant, 19, 1281, 10.1093/ndt/gfh128 Messa, 1998, Persistent secondary hyperparathiroidism after renal transplantation, Kidney Int, 54, 1704, 10.1046/j.1523-1755.1998.00142.x Reinhardt, 1998, Sequential changees of biochemical bone parameters after kidney transplantation, Nephrol Dial Transplant, 13, 436, 10.1093/oxfordjournals.ndt.a027843 Amer, 2013, Oral paricalcitol reduces the prevalence of postransplant hyperparathyroidism: Results of an open label randomized trial, Am J Transplant, XX, 1 González, 2013, Effects of oral paricalcitol on secondary yyperparathyroidism and proteinuria of kidney transplant patients, Transplantation, 95, e49, 10.1097/TP.0b013e3182855565 Boudville, 2006, Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients, Nephrol Dial Transplant, 21, 2621, 10.1093/ndt/gfl201 Giannini, 2010, Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: Role of calcium-sensing receptor polymorphisms and vitamin D deficiency, J Bone Min Research, 25, 841 Evenepoel, 2012, Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: A prospective observational study, Clin Transplant, 26, 393, 10.1111/j.1399-0012.2011.01524.x Perrin, 2013, Persistent hyperparathyroidism is a major risk factor for fractures in the fie years after kidney transplantation, Am J Transplant, 13, 2653, 10.1111/ajt.12425 Torres, 2004, Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation, Kidney Int, 65, 705, 10.1111/j.1523-1755.2004.00432.x Heaf, 2003, Hyperparathyroidism and long-term bone loss after renal transplantation, Clin Transplant, 17, 268, 10.1034/j.1399-0012.2003.00047.x Akaberi, 2006, Impact of parathyroid hormone on bone density in long-term renal transplant patients with good graft function, Transplantation, 82, 749, 10.1097/01.tp.0000230130.50451.78 Rojas, 2003, The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodelling, Kidney Int, 63, 1015, 10.1046/j.1523-1755.2003.00938.x Borchhardt, 2007, Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation, Am J Transplant, 7, 2515, 10.1111/j.1600-6143.2007.01950.x Bergua, 2008, Effect of cinacalcet on hypercalcemia and bone mineral density in renal trasplanted patients with secondary hyperparathyroidism, Transplantation, 86, 413, 10.1097/TP.0b013e31817c13e1 Courbebaisse, 2012, Effects of cinacalcet in renal transplant patients with hyperparathyroidism, Am J Nephrol, 35, 341, 10.1159/000337526 Leca, 2006, Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet, Am J Tranplant, 6, 2391, 10.1111/j.1600-6143.2006.01475.x Courbebaisse, 2009, Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients, Kidney Int, 75, 646, 10.1038/ki.2008.549 Graf, 1981, Renal phosphate wasting after successful kidney transplantation: 1-alpha vitamin D therapy in patients with normal parathyroid gland activity, Nephron, 28, 285, 10.1159/000182219 Lobo, 1995, Normocalcemic hyperparathyroidism associated with relatively low 1,25 vitamina D levels post-renal transplant can be succesfully treated with oral calcitriol, Clin Transplant, 9, 277 Jeffery, 2003, Prevalence and treatment of decreased bone density in renal transplant recipients: A randomized prospective trial of calcitriol versus alendronate, Tranplantation, 76, 1498, 10.1097/01.TP.0000092523.30277.13 Pérez Calderón, 1998, Tratamiento con calcitriol del hiperparatiroidismo normocalcémico en el paciente trasplantado, Nefrología, 18, 156 El-Agroudy, 2005, A prospective randomized study for prevention of postrenal transplantation bone loss, Kidney Int, 67, 2039, 10.1111/j.1523-1755.2005.00306.x Slatopolsky, 2002, Differential effects of 19-nor-1,25-(OH)2D2 and 1α-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats, Kidney Int, 62, 1277, 10.1111/j.1523-1755.2002.kid573.x Takahashi, 1997, A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content, Am J Kidney Dis, 30, 105, 10.1016/S0272-6386(97)90571-0 Mittman, 2010, Treatment of secondary hyperparathyroidism in ESRD: A 2-year, single-center crossover study, Kidney Int, 78, S33, 10.1038/ki.2010.191 Valle, 2008, Cinacalcet reduces the set point of PTH-calcium curve, J Am Soc Neprhol, 19, 2430, 10.1681/ASN.2007121320 De Francisco, 2008, Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet, Nephrol Dial Transplant, 23, 2895, 10.1093/ndt/gfn191 Mendoza, 2009, Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats, Amer J Physiol Renal Physiol., 296, F605, 10.1152/ajprenal.90272.2008 Komaba, 2010, Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism, Clin J Am Soc Nephrol, 5, 2305, 10.2215/CJN.02110310 Taniguchi, 2006, Persistent hyperparathyroidism in renal allograft recipients: Vitamin D receptor, calcium-sensing receptor, and apoptosis, Kidney Int, 70, 363, 10.1038/sj.ki.5001549 Bonarek, 1999, Reduced parathyroid functional mass after succesful kidney transplantation, Kidney Int, 56, 642, 10.1046/j.1523-1755.1999.00589.x Bravo, 2007, Successful kidney transplantation reduces hyperplastic parathyroid gland, Tranplant Proc, 39, 125, 10.1016/j.transproceed.2006.10.208 Lewin, 2002, Persistent downregulation of calcium-sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation, J Am Soc Nephrol, 13, 2110, 10.1097/01.ASN.0000024439.38838.03 Wu-Wong, 2010, Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis, Int J Endocrinol, 621687